Product approvals

In this Monday, June 17, 2019, photo, Joshua Ni, 24, and Fritz Ramirez, 23, vape from electronic cigarettes in San Francisco. San Francisco supervisors are considering whether to move the city toward becoming the first in the United States to ban all sales of electronic cigarettes in an effort to crack down on youth vaping. The plan would ban the sale and distribution of e-cigarettes, as well as prohibit e-cigarette manufacturing on city property. (AP Photo/Samantha Maldonado)
June 18, 2019 - 8:42 pm
SAN FRANCISCO (AP) — San Francisco supervisors moved a step closer Tuesday to becoming the first city in the U.S. to ban all sales of electronic cigarettes to crack down on youth vaping. Supervisors unanimously approved a ban on the sale and distribution of e-cigarettes. They also endorsed a ban on...
Read More
FILE - In this March 26, 2019, file photo, a baggage handler waits for luggage to arrive to sort and deliver to passengers at Dulles International Airport in Dulles, Va. The Transportation Security Administration has changed its cannabis policy to allow passengers to travel with some forms of CBD oil and a drug derived from marijuana that has been approved by the Food and Drug Administration. (AP Photo/Cliff Owen, File)
May 28, 2019 - 7:59 pm
WASHINGTON (AP) — The Transportation Security Administration has changed its cannabis policy to allow passengers to travel with some forms of CBD oil and a drug derived from marijuana that has been approved by the Food and Drug Administration. All forms of marijuana were previously prohibited in...
Read More
This photo provided by Novartis shows Zolgensma. The one-time gene therapy developed by Novartis, Zolgensma, will cost $2.125 million. It treats a rare condition called spinal muscular atrophy, or SMA, which strikes about 400 babies born in the U.S. each year. The therapy, given in a one-hour infusion, was approved for children under age 2 and will be available within two weeks. (Novartis via AP)
May 24, 2019 - 5:51 pm
U.S. regulators have approved the most expensive medicine ever, for a rare disorder that destroys a baby's muscle control and kills nearly all of those with the most common type of the disease within a couple of years. The treatment is priced at $2.125 million. Out-of-pocket costs for patients will...
Read More
This photo provided by Novartis shows Zolgensma. The one-time gene therapy developed by Novartis, Zolgensma, will cost $2.125 million. It treats a rare condition called spinal muscular atrophy, or SMA, which strikes about 400 babies born in the U.S. each year. The therapy, given in a one-hour infusion, was approved for children under age 2 and will be available within two weeks. (Novartis via AP)
May 24, 2019 - 2:35 pm
U.S. regulators have approved the most expensive medicine ever, for a disorder that destroys a baby's muscle control and kills nearly all of those with the most common variant of the disease within a couple years. The treatment is priced at $2.125 million. Out-of-pocket costs for patients will vary...
Read More
May 24, 2019 - 1:41 pm
U.S. regulators have approved the most expensive medicine ever, a therapy meant to cure a disorder that rapidly destroys a baby's muscle control and kills most within a couple years. The one-time gene therapy developed by Novartis, Zolgensma (zohl-JEN-smah), will cost $2.125 million. It treats a...
Read More
FILE - In this April 16, 2019, file photo, a woman exhales a puff of vapor from a Juul pen in Vancouver, Wash. Under intense scrutiny amid a wave of underage vaping, Juul is pushing into television with a multimillion-dollar campaign rebranding itself as a stop-smoking aid for adults trying to kick cigarettes. (AP Photo/Craig Mitchelldyer, File)
May 09, 2019 - 4:24 pm
WASHINGTON (AP) — The young models and the candy-colored graphics that helped propel Juul to the top of the e-cigarette market are gone. In their place are people like Carolyn, a 54-year-old former smoker featured in new TV commercials touting Juul as an alternative for middle-age smokers. "I don't...
Read More
FILE - In this April 16, 2019, file photo, a woman exhales a puff of vapor from a Juul pen in Vancouver, Wash. Under intense scrutiny amid a wave of underage vaping, Juul is pushing into television with a multimillion-dollar campaign rebranding itself as a stop-smoking aid for adults trying to kick cigarettes. (AP Photo/Craig Mitchelldyer, File)
May 09, 2019 - 3:42 pm
WASHINGTON (AP) — The young models and the candy-colored graphics that helped propel Juul to the top of the e-cigarette market are gone. In their place are people like Carolyn, a 54-year-old former smoker featured in new TV commercials touting Juul as an alternative for middle-age smokers. "I don't...
Read More
FILE - In this Friday, Jan. 4, 2018 file photo, a worker adds CBD oil to a drink at a coffee shop in Fort Lauderdale, Fla. Cannabidiol is one of more than 100 compounds found in marijuana. (Jennifer Lett/South Florida Sun-Sentinel via AP)/South Florida Sun-Sentinel via AP)
April 02, 2019 - 11:42 am
NEW YORK (AP) — U.S. regulators are planning a public hearing to collect more information on CBD in cosmetics, foods and other products as the cannabis compound spreads in popularity. CBD comes from marijuana or hemp plants but does not cause a high. People have been drawn to the extract because of...
Read More
FILE- In this March 11, 2019, file photo rescuers work at the scene of an Ethiopian Airlines flight crash near Bishoftu, or Debre Zeit, south of Addis Ababa, Ethiopia. Investigators have determined that an anti-stall system automatically activated before the Ethiopian Airlines Boeing 737 Max jet plunged into the ground, The Wall Street Journal reported Friday, March 29. (AP Photo/Mulugeta Ayene, File)
March 30, 2019 - 12:24 am
Boeing is facing mounting pressure to roll out a software update on its best-selling plane in time for airlines to use the jets during the peak summer travel season. Company engineers and test pilots are working to fix anti-stall technology on the Boeing 737 Max that is suspected to have played a...
Read More
FILE - This Oct. 14, 2015 file photo shows the Food & Drug Administration campus in Silver Spring, Md. On Friday, March 8, 2019, the FDA approved Roche’s Tecentriq, the first cancer immunotherapy for treating an aggressive type of breast cancer. (AP Photo/Andrew Harnik, File)
March 08, 2019 - 6:26 pm
The U.S. Food and Drug Administration has approved the first immunotherapy drug for breast cancer. Swiss drugmaker Roche's Tecentriq was OK'd Friday for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases. It's to be given with chemotherapy, the standard...
Read More

Pages